Navigation Links
Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
Date:5/13/2009

Results Show Superior Decrease in Pain Scores Compared to Saline

PARSIPPANY, N.J., May 13 /PRNewswire/ -- Ferring Pharmaceuticals recently presented the results of a six-month safety and efficacy study demonstrating that EUFLEXXA(R) (1% sodium hyaluronate) was effective at decreasing the pain of knee osteoarthritis (OA) at 26 weeks. The study showed that EUFLEXXA (R) is superior to saline in decreasing pain at 26 weeks in patients with OA of the knee.(1) The study results were presented by Dr. Roy D. Altman in a poster at the Annual Meeting of the American Academy of Orthopedic Surgeons on February 23, 2009.

EUFLEXXA(R) is a three-injection treatment regimen indicated for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. The goal of hyaluronic acid (HA) therapy is to reduce pain and improve physical function by replenishing the HA in human synovial fluid (fluid in joints). In OA, this fluid becomes thinner, leading to a decrease in elasticity and viscosity.

About the Study

The multicenter, 26-week, randomized, double-blind trial compared EUFLEXXA(R) and intra-articular buffered saline (IA-SA) for level of pain following a 50-Foot Walk Test, measured by 100 mm visual analog scale (VAS). The 586 patients with chronic idiopathic knee OA were randomized to treatment with either product in a 1:1 ratio. Each patient received one weekly injection for 3 weeks with 9 follow-up visits over 26 weeks after the first injection.

The EUFLEXXA(R) group showed an advantage over saline in pain reduction, with a larger mean decrease from baseline in pain scores: -25.7 (28.9) mm versus -18.5(32.5) mm respectively, with a least squares means of -6.6 mm (P=0.002). At 26 weeks, 145 (58%) of EUFLEXXA(R) subjects reported a greater than or equal to 20-mm improvement in pain based on the VAS scoring, compared with 120 (46%) in the o
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
2. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Former NASA scientist ... last week where he discussed Theradome™, the first portable ... The FOX segment shows firsthand how, via laser technology, ... loss solution that will not require surgery or medication.  ... at the base of the hair follicle, which is ...
(Date:5/4/2015)... and TORONTO , May 4, ... (OTCQB:GNBT) today announced that it intends to dividend to ... upon completion of a definitive licensing agreement to license ... ( www.smoofi.com ) (OTCQB:SMFI). As announced on ... of intent in respect of the licensing of its ...
(Date:5/4/2015)...  Impax Laboratories, Inc. (NASDAQ: IPXL ) announced ... appointing  Donna M. Hughes, as Senior Vice President, Human ... Vice President, Chief Compliance Officer. Both Ms. Hughes and ... Executive Officer, Fred Wilkinson . "We ... Impax team," said Fred Wilkinson , President and ...
Breaking Medicine Technology:FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3
... on complex cases, facility called ,future of hospital care, ... announces the opening of the Hamon Tower, the largest expansion ... intensive care for the region,s most critically ill patients. , ... new clinical programs for ICU patients, Hamon Tower is designed ...
... IRVINE, Calif., Oct. 2 ISTA Pharmaceuticals, Inc. (Nasdaq: ... financial results after market close on November 3, 2009. In ... p.m. Eastern Time to discuss these results and provide a ... , Time: 5:00 p.m. Eastern Time , Conference call ...
Cached Medicine Technology:Hamon Tower Features Critical Care Advances, Potential for Reduced Costs 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 During 2015-2019, ... a 7.7% CAGR. Currently, the European and APAC probiotic ... while the North American probiotic market lags behind owing ... population. , The North American probiotic market is ... 58%), followed by Canada and Mexico. The North American ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Malibu ... oral antiseptic breath spray. KissSafe™ is the first ... a safer experience while adding fresh breath appeal. ... and effectively kills germs in the mouth and ... also contains ingredients that possess additional wellness benefits. ...
(Date:5/4/2015)... 04, 2015 In a continuing effort ... substance absue, Per Wickstrom, the founder of Choices Recovery ... and the “Salute to the Oscars” celebration held ... the top floor of the luxurious Beverly Hilton Hotel. ... producer of sustainable product placement in TV and film, ...
(Date:5/4/2015)... New York (PRWEB) May 04, 2015 ... as $2.4 billion to settle thousands of Actos lawsuits ... diabetes medication increases the risk that a patient will ... on April 28th, if 95% of those eligible for ... resolve nearly 9,000 bladder cancer cases currently pending in ...
(Date:5/4/2015)... 2015 Getting patients to work with ... is critical to achieving the “triple aim” of better ... this will require a shift in thinking from stakeholders ... health systems move beyond their traditional boundaries to reach ... the third live meeting of the ACO and ...
Breaking Medicine News(10 mins):Health News:North America Probiotic Market to Increase by 2019, Announces MicroMarketMonitor in Its New Research Report Recently Published at MarketPublishers.com 2Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4
... in collaboration with,Siemens(R), AxisThree(R), Inc. of Pacific Palisades, ... Technology into the,Plastic Surgery office of Dr. Steve ... XS-300(TM), is the first of its kind, and ... combined with,innovative proprietary software. The XS-300(TM) platform photographs ...
... launch of its redesigned web site at www.oci.com , ... ... to meet the needs of its customers and target market, OCI is ... The site features improved content, an enhanced look and feel, and easy ...
... percent savings on medical services and healthcare products. , ... ... -- Allsup announced today it is offering a new http://www.allsup.com/Health-Discount-Program.aspx/?=PRJ2 ... of people with disabilities gain access to discounted healthcare and ...
... prescription drug samples distributed to children may be unsafe, ... Alliance and Hasbro Children,s Hospital. The national study, the ... children, appears in the October 2008 issue of ... as researchers at Harvard Medical School and the Warren ...
... long way toward helping severely obese individuals improve their ... to researchers at the Duke Diet and Fitness Center. ... average, just under one hour of exercise per week, ... life. They also reported improvements in their ability to ...
... Extendicare Skilled Nursing Facilities Named In Wash. Lawsuit, ... with,additional allegations in the class action lawsuit against ... the state of Washington [see,list by city at ... in,United States District Court, Western Washington Division, in ...
Cached Medicine News:Health News:Plan Your Breasts in 3-D 2Health News:Information Management Solutions Provider OCI Announces Redesign of Corporate Web Site 2Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 2Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 3Health News:Free drug samples carry risks for children 2Health News:A little exercise goes a long way for severely obese 2Health News:Additional Allegations Filed Against Elder Care Operator 2Health News:Additional Allegations Filed Against Elder Care Operator 3Health News:Additional Allegations Filed Against Elder Care Operator 4Health News:Additional Allegations Filed Against Elder Care Operator 5
... the only in-office test approved by the FDA ... BladderChek Test is a painless and non-invasive assay, ... elevated levels of NMP22 protein. Healthy individuals generally ... the urine. However, the level of NMP22 protein ...
Used for measuring rectal pressure during urodynamic studies. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open pack...
Used for suprapubic monitoring of bladder pressures. Suprapubic urodynamic studies avoid the effects of urethral catheterization and eliminate the need for a double bladder puncture. Supplied sterile...
... point-of-care (POC) diagnosis of patients with acute ... embolism. For use in doctors offices or ... counts, the Cardiac reader analyzer allows the ... D-Dimer from a single whole blood sample ...
Medicine Products: